<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33731">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667483</url>
  </required_header>
  <id_info>
    <org_study_id>DS5141-A-J101</org_study_id>
    <nct_id>NCT02667483</nct_id>
  </id_info>
  <brief_title>Study of DS-5141b in Patients With Duchenne Muscular Dystrophy</brief_title>
  <official_title>Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orphan Disease Treatment Institute Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <brief_summary>
    <textblock>
      This is a phase I/II study to evaluate the safety, tolerability, efficacy, and
      pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD)
      and to determine the dosage for subsequent studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number and severity of adverse events</measure>
    <time_frame>week 0 (baseline) to week 12</time_frame>
    <description>number and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax maximum concentration</measure>
    <time_frame>week 12</time_frame>
    <description>pharmacokinetic profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC area under the curve</measure>
    <time_frame>week 12</time_frame>
    <description>pharmacokinetic profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax time of maximum concentration</measure>
    <time_frame>week 12</time_frame>
    <description>pharmacokinetic profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 half-life</measure>
    <time_frame>week 12</time_frame>
    <description>pharmacokinetic profile</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>DS-5141b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-5141b, Subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-5141b</intervention_name>
    <description>DS-5141b, Subcutaneous injection</description>
    <arm_group_label>DS-5141b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of out-of-frame deletion(s) that could be corrected by dystrophin gene
             exon 45 skipping.

          -  Intact muscles of adequate quality for biopsy to allow evaluation of the efficacy of
             the study drug.

          -  Boys aged from 5 years to &lt;11 years.

          -  Patients able to walk at least 325 meters in the 6-minutes walk test.

          -  Glucocorticoid-naive patients, or patients who have used glucocorticoids for at least
             6 months prior to enrollment in this study with no dose changes for at least 3 months
             prior to enrollment.

        Exclusion Criteria:

          -  A genetic mutation that can not be expected the expression of dystrophin protein by
             dystrophin gene exon 45 skipping.

          -  A concurrent illness other than DMD that can cause muscle weakness and/or impairment
             of motor function.

          -  Current or history of severe disorder.

          -  Left ventricular ejection fraction (LEVF) &lt;55%.

          -  Corrected QT interval (QTc) &gt;0.45 sec.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Satoru Inoue</last_name>
    <phone>81-3-3492-3131</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Kodaira-shi</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>January 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>Oligonucleotides, Antisense</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
